2015-10-21 R2. 하효정 / 윤휘중 교수님 NEJM 2015-08. Introduction  Transplantation of hematopoietic cells  acute GVHD ?  The recipient and donor are HLA-DPB1–mismatched.

Slides:



Advertisements
Similar presentations
USRDS Clinical Indicators of Renal Allograft Loss Lawrence Y.C. Agodoa, MD FACP Jon J. Snyder, MS Bertram L. Kasiske, MD Allan J. Collins, MD FACP United.
Advertisements

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
林建廷 April 28,  IPSS for MDS (FAB classification) ◦ Greenberg P et al. International scoring system for evaluating prognosis in myelodysplastic.
Transplantation immunology Dr Adel Almogren.. Transfusion vs. Transplantation  Transfusion  transfer of blood  Ab-mediated reactions  Transplantation.
5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].
G. S / AIH 2006 Graft-versus-Host disease Physiopathology Gérard Socié, MD PhD Hospital Saint Louis Translating experimental into clinical knowledge.
Supported by Czech Govt. Funding MSM
Linkage. Announcements Problem set 1 is available for download. Due April 14. class videos are available from a link on the schedule web page, and at.
Linkage. Announcements Problem set 1 is available for download. Due April 14. class videos are available from a link on the schedule web page, and at.
Genetic Variations in NER Pathway, Smoking and 11 Cancer Sites: a Pooled Study Yi Ren Wang.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Allogeneic Stem Cell Transplantation for Acute Myeloid.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors N Engl J Med 2012;367: R3 Sunhee park/Prof. Kyung-sam cho.
Table S1: Antibodies Used for Flow Cytometric Analysis
Retrospective analysis of conditioning regimen containing decitabine of allogeneic stem cell transplantation for myelodysplastic syndrome and myeloproliterative.
Figure 1. Joint effect of rs and rs on prostate cancer aggressiveness and reclassification. (A) Joint effect of rs and rs on.
Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children  Daihong.
Transplantation Pathology
ASSOCIATIONS BETWEEN ANXA11 RS C/T, BTNL2 RS G/A, HLA CLASS I AND II POLYMORPHISMS AND SARCOIDOSIS EVOLUTION Manuel Vaz1, Bruno Lima2, Natália.
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.
HS 4160 Critical Scientific Analysis
Volume 18, Issue 1, Pages (January 2016)
Changes in the Clinical Impact of High-Risk Human Leukocyte Antigen Allele Mismatch Combinations on the Outcome of Unrelated Bone Marrow Transplantation 
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Cord blood transplantation and stem cell regenerative potential
Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation  Claudio G. Brunstein, Effie W. Petersdorf,
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation  Mats Remberger, Emma.
Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes  Junya Kanda, Kazuhiro Ikegame,
Identifying Permissible HLA-Mismatches in Unrelated-Donor Hematopoietic Stem-Cell Transplantation Using Predicted Indirectly Recognizable HLA Epitopes 
Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.
Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation 
Donor Selection for Killer Immunoglobulin-like Receptors B Haplotype of the Centromeric Motifs Can Improve the Outcome after HLA-Identical Sibling Hematopoietic.
Influence of Polymorphism within the Heme Oxygenase-I Promoter on Overall Survival and Transplantation-Related Mortality after Allogeneic Stem Cell Transplantation 
Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years  Masatsugu Tanaka, Koichi Miyamura,
Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source  Sharat Damodar,
Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.
Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young.
Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after.
Cytotoxic T-Lymphocyte Antigen-4 Single Nucleotide Polymorphisms Are Not Associated with Outcomes after Unrelated Donor Transplantation: A Center for.
HLA DNA Typing and Transplantation
Association between Genetic Variants in the Base Excision Repair Pathway and Outcomes after Hematopoietic Cell Transplantations  Bharat Thyagarajan, Bruce.
Higher CD34+ and CD3+ Cell Doses in the Graft Promote Long-Term Survival, and Have No Impact on the Incidence of Severe Acute or Chronic Graft-versus-Host.
Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.
Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.
Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.
Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.
Impact of HLA-DPB1 Haplotypes on Outcome of 10/10 Matched Unrelated Hematopoietic Stem Cell Donor Transplants Depends on MHC-Linked Microsatellite Polymorphisms 
Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant.
Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical.
High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Impact of Graft-versus-Host Disease on Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Leukemia-Lymphoma Focusing on Preconditioning Regimens:
Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches  David Gallardo, Anna Bosch-Vizcaya, Rocío Rodríguez-Romanos,
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.
Clinical Lymphoma, Myeloma and Leukemia
ADCY5 is expressed in isolated human islets and affected by T2D risk alleles. ADCY5 is expressed in isolated human islets and affected by T2D risk alleles.
Survival after HLA-Matched Sibling Donor HCT for ALL, Age ≥18 Years,
The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.
Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation  H Khoury, K Trinkaus, M.J Zhang, D Adkins,
Presentation transcript:

R2. 하효정 / 윤휘중 교수님 NEJM

Introduction  Transplantation of hematopoietic cells  acute GVHD ?  The recipient and donor are HLA-DPB1–mismatched  Risk, but the mechanisms are unknown.  ‘rs ’ is associated with HLA-DPB1 expression  GVHD risk correlates with the rs allele linked to the mismatched HLA-DPB1 in the recipient ??

METHOD Study Population  We genotyped rs in 3505 persons  Clinical outcomes : 2029 recipients of transplants from unrelated donors (acute leukemia, CML, MPS / between 1988 and 2008 )  1441 (only one HLA-DPB1 mismatched)  588 (HLA-A,B,C,DRB1,DQB1,DPB1–matched unrelated donor)

METHOD Genotyping and Linkage Analysis  Phasing : The three haplotypes  cell lines by first separating chromosomes  genotyping HLA-DPB1, rs , and rs on each haplotype

RESULT Effect of rs Allele on HLA-DPB1 Expression  rs AA : rs GG = : 24.95

RESULT Clinical Outcome grade II,III, or IV acute GVHD G-linked > A-linked Risk of relapse G-linked < A-linked  similar overall mortality

RESULT Clinical Outcome  In HLA-A,B,C,DRB1,DQB1,DPB1–matched transplantation Acute GVHD  rs G(+) > rs G (HR for 146 HLA-DPB1–matched rs AG transplants vs. 420 rs AA transplants, 1.86; 95% CI, 1.21 to 2.84; P = 0.004; and hazard ratio for 22 rs GG transplants vs. 420 rs AA transplants, 1.53; 95% CI, 0.55 to 4.25; P = 0.41)  Among rs A recipients of transplants from rs A donors Acute GVHD  rs G-linked > rs Alinked (HR for grade II, III, or IV acute GVHD, 1.60; 95% CI, 1.25 to 2.06; P<0.001; and hazard ratio for grade III or IV disease, 1.66; 95% CI, 1.16 to 2.35; P = 0.005)  rs is a better predictor of the risk of GVHD than is rs

RESULT Clinical Outcome  High risk of GVHD (T-cell epitope “nonpermissive”) & Low risk (“permissive”)  Associated with rs ? rs A in both recipient and donor (the A-A group) : 90.7% the G-G group : 31% Correlation between permissiveness indicated by T-cell epitope and permissiveness indicated by rs  The risk of grade III or IV acute GVHD epitope-permissive mismatches  A-G (HR 1.50), G-A (HR 1.38), G-G(HR 1.53) > A-A group epitope-nonpermissive mismatches  A-G (HR 1.03), G-A (HR 1.72), G-G(HR 1.70) > A-A group After isolation of the T-cell epitope effect, rs contributes additional information about the risk of GVHD

RESULT Probability of Finding Donors with a Permissible HLA-DPB1 Mismatch  one or two rs G-linked HLA-DPB1 alleles rs AG (55 recipients) or rs GG (15 recipients) 1. Among 55 recipients with rs AG : 30 (55%) had acceptable donors, the other 25 (45%) had only donors with a mismatch for the recipient’s rs G-linked HLA-DPB1 2. None of the 15 recipients with rs GG had HLA-DPB1– matched donors.  Recipients with rs AA rs AA(76 recipients ) (50%) (either completely matched or matched for graft-versus-host allorecognition) (42%) (mismatched for one HLA-DPB1 allele) 3. 6 (8%) (mismathced for two HLA-DPB1 allele)

Conslusion  The risk of GVHD associated with HLA-DPB1 mismatching was influenced by the HLA-DPB1 rs expression marker.  Among recipients of HLA-DPB1–mismatched transplants from donors with the low-expression allele, recipients with the high expression allele had a high risk of GVHD